|Mr. Thomas Charles Reilly||Chief Financial Officer||856.49k||N/A||1972|
|Dr. Steven B. Ketchum Ph.D.||Pres of R&D and Chief Scientific Officer||991.19k||N/A||1965|
|Mr. Aaron D. Berg||Exec. VP & Pres of U.S.||913.7k||N/A||1963|
|Mr. Patrick Holt||Pres, CEO & Director||N/A||N/A||N/A|
|Mr. Jordan Zwick||Sr. VP of Corp. Bus. Devel. & Investor Relations||N/A||N/A||1987|
|Ms. Donna Pasek||Sr. VP of HR||N/A||N/A||N/A|
|Mr. Laurent Abuaf||Pres of Europe & Sr. VP||N/A||N/A||N/A|
|Dr. Nabil Abadir||Chief Medical Officer of Global Medical Affairs||N/A||N/A||N/A|
|Dr. David Keenan Ph.D.||Exec. VP of Technical Operations & Pres of Europe||N/A||N/A||N/A|
Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, European countries, Canada, Lebanon, and the United Arab Emirates. It offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. The company sells its products principally to wholesalers and specialty pharmacy providers. It has a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commercialize drug products and indications based on the active pharmaceutical ingredient in Vascepa. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was incorporated in 1989 and is headquartered in Dublin, Ireland.
Amarin Corporation plc’s ISS Governance QualityScore as of September 1, 2023 is 7. The pillar scores are Audit: 9; Board: 4; Shareholder Rights: 7; Compensation: 7.